APO Research
Talk to an analyst

APO RESEARCH · REPORT

CAR-T Therapy For B-Cell Malignancies

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global CAR-T Therapy For B-Cell Malignancies Industry Growth and Trends Forecast to 2032

23 December 2025112 pages

Choose your research edition.

Industry ResearchCAR-T Therapy For B-Cell Malignancies Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal CAR-T Therapy For B-Cell Malignancies Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal CAR-T Therapy For B-Cell Malignancies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CAR-T Therapy For B-Cell Malignancies Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal CAR-T Therapy For B-Cell Malignancies Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

According to APO Research, the global CAR-T Therapy For B-Cell Malignancies market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for CAR-T Therapy For B-Cell Malignancies is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for CAR-T Therapy For B-Cell Malignancies is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for CAR-T Therapy For B-Cell Malignancies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the CAR-T Therapy For B-Cell Malignancies market include IMCURE, JW Therapeutics, Johnson And Johnson, Novartis, Roche, CARsgen Therapeutics, Chongqing Precision Biotech, Gilead Sciences and HEBECELL, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global CAR-T Therapy For B-Cell Malignancies market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The CAR-T Therapy For B-Cell Malignancies market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global CAR-T Therapy For B-Cell Malignancies market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to CAR-T Therapy For B-Cell Malignancies.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global CAR-T Therapy For B-Cell Malignancies market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

CAR-T Therapy For B-Cell Malignancies Market by Company

IMCURE

JW Therapeutics

Johnson And Johnson

Novartis

Roche

CARsgen Therapeutics

Chongqing Precision Biotech

Gilead Sciences

HEBECELL

Fosun Kite Bio

Legend Biotech

Beihai Biotechnology

AstraZeneca

Regeneron Pharmaceuticals

Kite Pharma

Celgene

Bristol Myers Squibb

Bluebird Bio

CAR-T Therapy For B-Cell Malignancies Segment by Type

Universal CAR-T

Dual Targets CAR-T

Gene Modified Enhanced CAR-T

Multi Targets CAR-T

Single Target CAR-T

CAR-T Therapy For B-Cell Malignancies Segment by Application

Multiple Myeloma

B-Cell Acute Lymphoblastic Leukemia

B-Cell Non-Hodgkin's Lymphoma

Others

CAR-T Therapy For B-Cell Malignancies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CAR-T Therapy For B-Cell Malignancies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CAR-T Therapy For B-Cell Malignancies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CAR-T Therapy For B-Cell Malignancies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of CAR-T Therapy For B-Cell Malignancies companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global CAR-T Therapy For B-Cell Malignancies Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global CAR-T Therapy For B-Cell Malignancies Market Size by Region (2021-2026) & (US$ Million) Table 3. Global CAR-T Therapy For B-Cell Malignancies Market Share by Region (2021-2026) Table 4. Global CAR-T Therapy For B-Cell Malignancies Market Size by Region (2027-2032) & (US$ Million) Table 5. Global CAR-T Therapy For B-Cell Malignancies Market Share by Region (2027-2032) Table 6. Global CAR-T Therapy For B-Cell Malignancies Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global CAR-T Therapy For B-Cell Malignancies Market Size by Type (2021-2026) & (US$ Million) Table 8. Global CAR-T Therapy For B-Cell Malignancies Market Size Share by Type (2021-2026) Table 9. Global CAR-T Therapy For B-Cell Malignancies Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global CAR-T Therapy For B-Cell Malignancies Market Size Share Forecasted by Type (2027-2032) Table 11. North America CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global CAR-T Therapy For B-Cell Malignancies Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global CAR-T Therapy For B-Cell Malignancies Market Size by Application (2021-2026) & (US$ Million) Table 23. Global CAR-T Therapy For B-Cell Malignancies Market Size Share by Application (2021-2026) Table 24. Global CAR-T Therapy For B-Cell Malignancies Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global CAR-T Therapy For B-Cell Malignancies Market Size Share Forecasted by Application (2027-2032) Table 26. North America CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. CAR-T Therapy For B-Cell Malignancies Industry Trends Table 37. CAR-T Therapy For B-Cell Malignancies Industry Drivers Table 38. CAR-T Therapy For B-Cell Malignancies Industry Opportunities and Challenges Table 39. CAR-T Therapy For B-Cell Malignancies Industry Restraints Table 40. Global CAR-T Therapy For B-Cell Malignancies Revenue by Company (US$ Million) & (2021-2026) Table 41. Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Company (2021-2026) Table 42. Global CAR-T Therapy For B-Cell Malignancies Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global CAR-T Therapy For B-Cell Malignancies Key Company Headquarters & Area Served Table 44. Global CAR-T Therapy For B-Cell Malignancies Company, Product Type & Application Table 45. Global CAR-T Therapy For B-Cell Malignancies Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global CAR-T Therapy For B-Cell Malignancies by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. IMCURE Company Information Table 49. IMCURE Business Overview Table 50. IMCURE CAR-T Therapy For B-Cell Malignancies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. IMCURE CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 52. IMCURE Recent Development Table 53. JW Therapeutics Company Information Table 54. JW Therapeutics Business Overview Table 55. JW Therapeutics CAR-T Therapy For B-Cell Malignancies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. JW Therapeutics CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 57. JW Therapeutics Recent Development Table 58. Johnson And Johnson Company Information Table 59. Johnson And Johnson Business Overview Table 60. Johnson And Johnson CAR-T Therapy For B-Cell Malignancies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Johnson And Johnson CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 62. Johnson And Johnson Recent Development Table 63. Novartis Company Information Table 64. Novartis Business Overview Table 65. Novartis CAR-T Therapy For B-Cell Malignancies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Novartis CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 67. Novartis Recent Development Table 68. Roche Company Information Table 69. Roche Business Overview Table 70. Roche CAR-T Therapy For B-Cell Malignancies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Roche CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 72. Roche Recent Development Table 73. CARsgen Therapeutics Company Information Table 74. CARsgen Therapeutics Business Overview Table 75. CARsgen Therapeutics CAR-T Therapy For B-Cell Malignancies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. CARsgen Therapeutics CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 77. CARsgen Therapeutics Recent Development Table 78. Chongqing Precision Biotech Company Information Table 79. Chongqing Precision Biotech Business Overview Table 80. Chongqing Precision Biotech CAR-T Therapy For B-Cell Malignancies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Chongqing Precision Biotech CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 82. Chongqing Precision Biotech Recent Development Table 83. Gilead Sciences Company Information Table 84. Gilead Sciences Business Overview Table 85. Gilead Sciences CAR-T Therapy For B-Cell Malignancies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Gilead Sciences CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 87. Gilead Sciences Recent Development Table 88. HEBECELL Company Information Table 89. HEBECELL Business Overview Table 90. HEBECELL CAR-T Therapy For B-Cell Malignancies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. HEBECELL CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 92. HEBECELL Recent Development Table 93. Fosun Kite Bio Company Information Table 94. Fosun Kite Bio Business Overview Table 95. Fosun Kite Bio CAR-T Therapy For B-Cell Malignancies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Fosun Kite Bio CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 97. Fosun Kite Bio Recent Development Table 98. Legend Biotech Company Information Table 99. Legend Biotech Business Overview Table 100. Legend Biotech CAR-T Therapy For B-Cell Malignancies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Legend Biotech CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 102. Legend Biotech Recent Development Table 103. Beihai Biotechnology Company Information Table 104. Beihai Biotechnology Business Overview Table 105. Beihai Biotechnology CAR-T Therapy For B-Cell Malignancies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Beihai Biotechnology CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 107. Beihai Biotechnology Recent Development Table 108. AstraZeneca Company Information Table 109. AstraZeneca Business Overview Table 110. AstraZeneca CAR-T Therapy For B-Cell Malignancies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. AstraZeneca CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 112. AstraZeneca Recent Development Table 113. Regeneron Pharmaceuticals Company Information Table 114. Regeneron Pharmaceuticals Business Overview Table 115. Regeneron Pharmaceuticals CAR-T Therapy For B-Cell Malignancies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Regeneron Pharmaceuticals CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 117. Regeneron Pharmaceuticals Recent Development Table 118. Kite Pharma Company Information Table 119. Kite Pharma Business Overview Table 120. Kite Pharma CAR-T Therapy For B-Cell Malignancies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Kite Pharma CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 122. Kite Pharma Recent Development Table 123. Celgene Company Information Table 124. Celgene Business Overview Table 125. Celgene CAR-T Therapy For B-Cell Malignancies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Celgene CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 127. Celgene Recent Development Table 128. Bristol Myers Squibb Company Information Table 129. Bristol Myers Squibb Business Overview Table 130. Bristol Myers Squibb CAR-T Therapy For B-Cell Malignancies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. Bristol Myers Squibb CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 132. Bristol Myers Squibb Recent Development Table 133. Bluebird Bio Company Information Table 134. Bluebird Bio Business Overview Table 135. Bluebird Bio CAR-T Therapy For B-Cell Malignancies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. Bluebird Bio CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 137. Bluebird Bio Recent Development Table 138. North America CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. North America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021-2026) & (US$ Million) Table 140. North America CAR-T Therapy For B-Cell Malignancies Market Share by Country (2021-2026) Table 141. North America CAR-T Therapy For B-Cell Malignancies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. North America CAR-T Therapy For B-Cell Malignancies Market Share Forecast by Country (2027-2032) Table 143. Europe CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Europe CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021-2026) & (US$ Million) Table 145. Europe CAR-T Therapy For B-Cell Malignancies Market Share by Country (2021-2026) Table 146. Europe CAR-T Therapy For B-Cell Malignancies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Europe CAR-T Therapy For B-Cell Malignancies Market Share Forecast by Country (2027-2032) Table 148. Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021-2026) & (US$ Million) Table 150. Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Share by Country (2021-2026) Table 151. Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Share Forecast by Country (2027-2032) Table 153. Latin America CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Latin America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021-2026) & (US$ Million) Table 155. Latin America CAR-T Therapy For B-Cell Malignancies Market Share by Country (2021-2026) Table 156. Latin America CAR-T Therapy For B-Cell Malignancies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Latin America CAR-T Therapy For B-Cell Malignancies Market Share Forecast by Country (2027-2032) Table 158. Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021-2026) & (US$ Million) Table 160. Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Share by Country (2021-2026) Table 161. Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Share Forecast by Country (2027-2032) Table 163. Research Programs/Design for This Report Table 164. Authors List of This Report Table 165. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. CAR-T Therapy For B-Cell Malignancies Product Image Figure 3. Global CAR-T Therapy For B-Cell Malignancies Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 5. Global CAR-T Therapy For B-Cell Malignancies Market Share by Region: 2025 VS 2032 Figure 6. Global CAR-T Therapy For B-Cell Malignancies Market Share by Region (2021-2032) Figure 7. North America CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Universal CAR-T Image Figure 13. Global Universal CAR-T Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Dual Targets CAR-T Image Figure 15. Global Dual Targets CAR-T Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Gene Modified Enhanced CAR-T Image Figure 17. Global Gene Modified Enhanced CAR-T Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Multi Targets CAR-T Image Figure 19. Global Multi Targets CAR-T Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Single Target CAR-T Image Figure 21. Global Single Target CAR-T Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. Global CAR-T Therapy For B-Cell Malignancies Market Size Overview by Type (2021-2032) & (US$ Million) Figure 23. Global CAR-T Therapy For B-Cell Malignancies Market Share by Type 2025 VS 2032 Figure 24. North America CAR-T Therapy For B-Cell Malignancies Market Size Share by Type (2021-2032) Figure 25. Europe CAR-T Therapy For B-Cell Malignancies Market Size Share by Type (2021-2032) Figure 26. Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size Share by Type (2021-2032) Figure 27. Latin America CAR-T Therapy For B-Cell Malignancies Market Size Share by Type (2021-2032) Figure 28. Middle East and Africa CAR-T Therapy For B-Cell Malignancies Market Size Share by Type (2021-2032) Figure 29. Multiple Myeloma Image Figure 30. Global Multiple Myeloma Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. B-Cell Acute Lymphoblastic Leukemia Image Figure 32. Global B-Cell Acute Lymphoblastic Leukemia Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. B-Cell Non-Hodgkin's Lymphoma Image Figure 34. Global B-Cell Non-Hodgkin's Lymphoma Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Others Image Figure 36. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Global CAR-T Therapy For B-Cell Malignancies Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global CAR-T Therapy For B-Cell Malignancies Market Share by Application 2025 VS 2032 Figure 39. North America CAR-T Therapy For B-Cell Malignancies Market Size Share by Application (2021-2032) Figure 40. Europe CAR-T Therapy For B-Cell Malignancies Market Size Share by Application (2021-2032) Figure 41. Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size Share by Application (2021-2032) Figure 42. Latin America CAR-T Therapy For B-Cell Malignancies Market Size Share by Application (2021-2032) Figure 43. Middle East and Africa CAR-T Therapy For B-Cell Malignancies Market Size Share by Application (2021-2032) Figure 44. Global Top 5 and 10 CAR-T Therapy For B-Cell Malignancies Players Market Share by Revenue in 2025 Figure 45. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 46. North America CAR-T Therapy For B-Cell Malignancies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 47. North America CAR-T Therapy For B-Cell Malignancies Market Share by Country: 2021 VS 2025 VS 2032 Figure 48. North America CAR-T Therapy For B-Cell Malignancies Market Share by Country (2021-2032) Figure 49. Europe CAR-T Therapy For B-Cell Malignancies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe CAR-T Therapy For B-Cell Malignancies Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe CAR-T Therapy For B-Cell Malignancies Market Share by Country (2021-2032) Figure 52. Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 53. Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Share by Country: 2021 VS 2025 VS 2032 Figure 54. Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Share by Country (2021-2032) Figure 55. Latin America CAR-T Therapy For B-Cell Malignancies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America CAR-T Therapy For B-Cell Malignancies Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America CAR-T Therapy For B-Cell Malignancies Market Share by Country (2021-2032) Figure 58. Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Share by Country: 2021 VS 2025 VS 2032 Figure 60. Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Share by Country (2021-2032) Figure 61. Years Considered Figure 62. Research Process Figure 63. Key Executives Interviewed

Scope & coverage.

Types
  • Universal CAR-T
  • Dual Targets CAR-T
  • Gene Modified Enhanced CAR-T
  • Multi Targets CAR-T
  • Single Target CAR-T
Applications
  • Multiple Myeloma
  • B-Cell Acute Lymphoblastic Leukemia
  • B-Cell Non-Hodgkin's Lymphoma
  • Others
Companies covered
  • IMCURE
  • JW Therapeutics
  • Johnson And Johnson
  • Novartis
  • Roche
  • CARsgen Therapeutics
  • Chongqing Precision Biotech
  • Gilead Sciences
  • HEBECELL
  • Fosun Kite Bio
  • Legend Biotech
  • Beihai Biotechnology
  • AstraZeneca
  • Regeneron Pharmaceuticals
  • Kite Pharma
  • Celgene
  • Bristol Myers Squibb
  • Bluebird Bio

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global CAR-T Therapy For B-Cell Malignancies Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global CAR-T Therapy For B-Cell Malignancies Market Size by Region (2021-2032)
  5. 1.4.1 Global CAR-T Therapy For B-Cell Malignancies Market Size by Region (2021-2026)
  6. 1.4.2 Global CAR-T Therapy For B-Cell Malignancies Market Size by Region (2027-2032)
  7. 1.5 Key Regions CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032)
  8. 1.5.1 North America CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate (2021-2032)
2 CAR-T Therapy For B-Cell Malignancies Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Universal CAR-T
  3. 2.1.2 Dual Targets CAR-T
  4. 2.1.3 Gene Modified Enhanced CAR-T
  5. 2.1.4 Multi Targets CAR-T
  6. 2.1.5 Single Target CAR-T
  7. 2.2 Global CAR-T Therapy For B-Cell Malignancies Market Size by Type
  8. 2.2.1 Global CAR-T Therapy For B-Cell Malignancies Market Size Overview by Type (2021-2032)
  9. 2.2.2 Global CAR-T Therapy For B-Cell Malignancies Historic Market Size Review by Type (2021-2026)
  10. 2.2.3 Global CAR-T Therapy For B-Cell Malignancies Market Size Forecasted by Type (2027-2032)
  11. 2.3 Global CAR-T Therapy For B-Cell Malignancies Market Size by Regions
  12. 2.3.1 North America CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Type (2021-2026)
  13. 2.3.2 Europe CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Type (2021-2026)
  14. 2.3.3 Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Type (2021-2026)
  15. 2.3.4 South America CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Type (2021-2026)
  16. 2.3.5 Middle East and Africa CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Type (2021-2026)
3 CAR-T Therapy For B-Cell Malignancies Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Multiple Myeloma
  3. 3.1.2 B-Cell Acute Lymphoblastic Leukemia
  4. 3.1.3 B-Cell Non-Hodgkin's Lymphoma
  5. 3.1.4 Others
  6. 3.2 Global CAR-T Therapy For B-Cell Malignancies Market Size by Application
  7. 3.2.1 Global CAR-T Therapy For B-Cell Malignancies Market Size Overview by Application (2021-2032)
  8. 3.2.2 Global CAR-T Therapy For B-Cell Malignancies Historic Market Size Review by Application (2021-2026)
  9. 3.2.3 Global CAR-T Therapy For B-Cell Malignancies Market Size Forecasted by Application (2027-2032)
  10. 3.3 Global CAR-T Therapy For B-Cell Malignancies Market Size by Regions
  11. 3.3.1 North America CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Application (2021-2026)
  12. 3.3.2 Europe CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Application (2021-2026)
  13. 3.3.3 Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Application (2021-2026)
  14. 3.3.4 South America CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Application (2021-2026)
  15. 3.3.5 Middle East and Africa CAR-T Therapy For B-Cell Malignancies Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 CAR-T Therapy For B-Cell Malignancies Industry Trends
  2. 4.2 CAR-T Therapy For B-Cell Malignancies Industry Drivers
  3. 4.3 CAR-T Therapy For B-Cell Malignancies Industry Opportunities and Challenges
  4. 4.4 CAR-T Therapy For B-Cell Malignancies Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by CAR-T Therapy For B-Cell Malignancies Revenue (2021-2026)
  2. 5.2 Global CAR-T Therapy For B-Cell Malignancies Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global CAR-T Therapy For B-Cell Malignancies Key Company Headquarters & Area Served
  4. 5.4 Global CAR-T Therapy For B-Cell Malignancies Company, Product Type & Application
  5. 5.5 Global CAR-T Therapy For B-Cell Malignancies Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global CAR-T Therapy For B-Cell Malignancies Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 CAR-T Therapy For B-Cell Malignancies Players Market Share by Revenue in 2025
  9. 5.6.3 2025 CAR-T Therapy For B-Cell Malignancies Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 IMCURE
  2. 6.1.1 IMCURE Company Information
  3. 6.1.2 IMCURE Business Overview
  4. 6.1.3 IMCURE CAR-T Therapy For B-Cell Malignancies Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 IMCURE CAR-T Therapy For B-Cell Malignancies Product Portfolio
  6. 6.1.5 IMCURE Recent Developments
  7. 6.2 JW Therapeutics
  8. 6.2.1 JW Therapeutics Company Information
  9. 6.2.2 JW Therapeutics Business Overview
  10. 6.2.3 JW Therapeutics CAR-T Therapy For B-Cell Malignancies Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 JW Therapeutics CAR-T Therapy For B-Cell Malignancies Product Portfolio
  12. 6.2.5 JW Therapeutics Recent Developments
  13. 6.3 Johnson And Johnson
  14. 6.3.1 Johnson And Johnson Company Information
  15. 6.3.2 Johnson And Johnson Business Overview
  16. 6.3.3 Johnson And Johnson CAR-T Therapy For B-Cell Malignancies Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Johnson And Johnson CAR-T Therapy For B-Cell Malignancies Product Portfolio
  18. 6.3.5 Johnson And Johnson Recent Developments
  19. 6.4 Novartis
  20. 6.4.1 Novartis Company Information
  21. 6.4.2 Novartis Business Overview
  22. 6.4.3 Novartis CAR-T Therapy For B-Cell Malignancies Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Novartis CAR-T Therapy For B-Cell Malignancies Product Portfolio
  24. 6.4.5 Novartis Recent Developments
  25. 6.5 Roche
  26. 6.5.1 Roche Company Information
  27. 6.5.2 Roche Business Overview
  28. 6.5.3 Roche CAR-T Therapy For B-Cell Malignancies Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Roche CAR-T Therapy For B-Cell Malignancies Product Portfolio
  30. 6.5.5 Roche Recent Developments
  31. 6.6 CARsgen Therapeutics
  32. 6.6.1 CARsgen Therapeutics Company Information
  33. 6.6.2 CARsgen Therapeutics Business Overview
  34. 6.6.3 CARsgen Therapeutics CAR-T Therapy For B-Cell Malignancies Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 CARsgen Therapeutics CAR-T Therapy For B-Cell Malignancies Product Portfolio
  36. 6.6.5 CARsgen Therapeutics Recent Developments
  37. 6.7 Chongqing Precision Biotech
  38. 6.7.1 Chongqing Precision Biotech Company Information
  39. 6.7.2 Chongqing Precision Biotech Business Overview
  40. 6.7.3 Chongqing Precision Biotech CAR-T Therapy For B-Cell Malignancies Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Chongqing Precision Biotech CAR-T Therapy For B-Cell Malignancies Product Portfolio
  42. 6.7.5 Chongqing Precision Biotech Recent Developments
  43. 6.8 Gilead Sciences
  44. 6.8.1 Gilead Sciences Company Information
  45. 6.8.2 Gilead Sciences Business Overview
  46. 6.8.3 Gilead Sciences CAR-T Therapy For B-Cell Malignancies Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Gilead Sciences CAR-T Therapy For B-Cell Malignancies Product Portfolio
  48. 6.8.5 Gilead Sciences Recent Developments
  49. 6.9 HEBECELL
  50. 6.9.1 HEBECELL Company Information
  51. 6.9.2 HEBECELL Business Overview
  52. 6.9.3 HEBECELL CAR-T Therapy For B-Cell Malignancies Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 HEBECELL CAR-T Therapy For B-Cell Malignancies Product Portfolio
  54. 6.9.5 HEBECELL Recent Developments
  55. 6.10 Fosun Kite Bio
  56. 6.10.1 Fosun Kite Bio Company Information
  57. 6.10.2 Fosun Kite Bio Business Overview
  58. 6.10.3 Fosun Kite Bio CAR-T Therapy For B-Cell Malignancies Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Fosun Kite Bio CAR-T Therapy For B-Cell Malignancies Product Portfolio
  60. 6.10.5 Fosun Kite Bio Recent Developments
  61. 6.11 Legend Biotech
  62. 6.11.1 Legend Biotech Company Information
  63. 6.11.2 Legend Biotech Business Overview
  64. 6.11.3 Legend Biotech CAR-T Therapy For B-Cell Malignancies Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Legend Biotech CAR-T Therapy For B-Cell Malignancies Product Portfolio
  66. 6.11.5 Legend Biotech Recent Developments
  67. 6.12 Beihai Biotechnology
  68. 6.12.1 Beihai Biotechnology Company Information
  69. 6.12.2 Beihai Biotechnology Business Overview
  70. 6.12.3 Beihai Biotechnology CAR-T Therapy For B-Cell Malignancies Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Beihai Biotechnology CAR-T Therapy For B-Cell Malignancies Product Portfolio
  72. 6.12.5 Beihai Biotechnology Recent Developments
  73. 6.13 AstraZeneca
  74. 6.13.1 AstraZeneca Company Information
  75. 6.13.2 AstraZeneca Business Overview
  76. 6.13.3 AstraZeneca CAR-T Therapy For B-Cell Malignancies Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 AstraZeneca CAR-T Therapy For B-Cell Malignancies Product Portfolio
  78. 6.13.5 AstraZeneca Recent Developments
  79. 6.14 Regeneron Pharmaceuticals
  80. 6.14.1 Regeneron Pharmaceuticals Company Information
  81. 6.14.2 Regeneron Pharmaceuticals Business Overview
  82. 6.14.3 Regeneron Pharmaceuticals CAR-T Therapy For B-Cell Malignancies Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Regeneron Pharmaceuticals CAR-T Therapy For B-Cell Malignancies Product Portfolio
  84. 6.14.5 Regeneron Pharmaceuticals Recent Developments
  85. 6.15 Kite Pharma
  86. 6.15.1 Kite Pharma Company Information
  87. 6.15.2 Kite Pharma Business Overview
  88. 6.15.3 Kite Pharma CAR-T Therapy For B-Cell Malignancies Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Kite Pharma CAR-T Therapy For B-Cell Malignancies Product Portfolio
  90. 6.15.5 Kite Pharma Recent Developments
  91. 6.16 Celgene
  92. 6.16.1 Celgene Company Information
  93. 6.16.2 Celgene Business Overview
  94. 6.16.3 Celgene CAR-T Therapy For B-Cell Malignancies Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Celgene CAR-T Therapy For B-Cell Malignancies Product Portfolio
  96. 6.16.5 Celgene Recent Developments
  97. 6.17 Bristol Myers Squibb
  98. 6.17.1 Bristol Myers Squibb Company Information
  99. 6.17.2 Bristol Myers Squibb Business Overview
  100. 6.17.3 Bristol Myers Squibb CAR-T Therapy For B-Cell Malignancies Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 Bristol Myers Squibb CAR-T Therapy For B-Cell Malignancies Product Portfolio
  102. 6.17.5 Bristol Myers Squibb Recent Developments
  103. 6.18 Bluebird Bio
  104. 6.18.1 Bluebird Bio Company Information
  105. 6.18.2 Bluebird Bio Business Overview
  106. 6.18.3 Bluebird Bio CAR-T Therapy For B-Cell Malignancies Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 Bluebird Bio CAR-T Therapy For B-Cell Malignancies Product Portfolio
  108. 6.18.5 Bluebird Bio Recent Developments
7 North America
  1. 7.1 North America CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021-2026)
  3. 7.3 North America CAR-T Therapy For B-Cell Malignancies Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021-2026)
  3. 8.3 Europe CAR-T Therapy For B-Cell Malignancies Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021-2026)
  3. 10.3 South America CAR-T Therapy For B-Cell Malignancies Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst